Geron Corporation (GERN) Stock Grade

About Geron Corporation's fundamentals

Geron Corporation is a biotechnology company with a market capitalization of $801.9 million that has demonstrated significant revenue momentum, with year-over-year growth of 138.8%. However, the company is currently unprofitable, operating with a net margin of -46.7% and reporting a net loss in its latest annual statement. The company does not pay a dividend, and traditional valuation metrics like P/E ratio and return on equity are not applicable due to its loss-making status. This profile is typical of early-stage or development-focused biotech firms investing heavily in research and product advancement.